Table 5.
Base case and scenario analysis results per patient identified as at high risk by HepCATT intervention
| Testing option | Total costs | Total QALYs | Incremental costs | Incremental QALYs | ICER |
|---|---|---|---|---|---|
| Base case results: | |||||
| Control arm | £417 | 16.2207 | - | - | - |
| Intervention arm | £424 | 16.2218 | £7.45 | 0.00108 | £6916 |
| Training costs excluded: | |||||
| Control arm | £417 | 16.2207 | - | - | - |
| Intervention arm | £423 | 16.2218 | £6.23 | 0.00108 | £5783 |
| Scenario—no treatment effect for linkage to care (referral and attendance): | |||||
| Control arm | £416 | 16.2212 | - | - | - |
| Intervention arm | £424 | 16.2216 | £8.56 | 0.00044 | £19 289 |
| Scenario: £5000 per DAA: | |||||
| Control arm | £389 | 16.2207 | - | - | - |
| Intervention arm | £395 | 16.2218 | £5.52 | 0.00108 | £5126 |
| Scenario—utility adjusted to PWID utilities (all multiplied by 0.82): | |||||
| Control arm | £417 | 13.2557 | |||
| Intervention arm | £424 | 13.2565 | £7.45 | 0.00088 | £8463 |
DAA=direct acting antiviral; ICER=incremental cost effectiveness ratio; PWID=people who inject drugs; QALY=quality adjusted life year.